Trial Profile
The effectiveness and safety of lobaplatin or carboplatin combined with paclitaxel for locally advanced and metastatic non-small cell lung cancer: a prospective, dynamic randomized, positive controlled, multi-center phase clinical trial.
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 25 Nov 2020
Price :
$35
*
At a glance
- Drugs Lobaplatin (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 21 May 2012 Planned end date changed from 1 Dec 2011 to 29 Feb 2012 as reported by Chinese Clinical Trial Register.
- 29 Mar 2011 New trial record